See the DrugPatentWatch profile for Fondaparinux
The brand name for fondaparinux is Arixtra [1].
What is Arixtra used for?
Arixtra is a medication used for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip fracture surgery, hip replacement surgery, or knee replacement surgery [2]. It is also used for the treatment of DVT and PE in patients who have not undergone surgery [2].
How does fondaparinux work?
Fondaparinux is a synthetic, selective indirect inhibitor of activated Factor X (Xa) [2]. It works by binding to antithrombin III, which in turn inactivates Factor Xa [2]. This action interrupts the coagulation cascade, preventing the formation of blood clots [2].
When does the patent for Arixtra expire?
The patent exclusivity for Arixtra has a complex history. According to DrugPatentWatch.com, the initial patents have expired, but there may be ongoing patent challenges and exclusivities related to different formulations or indications [3]. Specific patent expiration dates can vary by region and are subject to legal proceedings [3].
Are there generic versions of Arixtra available?
As of the information available, the development and approval of generic versions of fondaparinux have faced legal and regulatory hurdles, often related to patent disputes [3]. Companies may seek to market generic alternatives once all relevant patent protections and exclusivities have been resolved [3].
What are the risks associated with Arixtra?
The primary risk associated with Arixtra is an increased risk of bleeding [2]. Other potential side effects include anemia, dizziness, insomnia, headache, and nausea [2]. It is important to discuss these risks with a healthcare provider before starting treatment [2].